TY - JOUR
T1 - Towards global consensus on outcome measures for atopic eczema research
T2 - Results of the HOME II meeting
AU - Schmitt, Jochen
AU - Spuls, Phyllis
AU - Boers, Maarten
AU - Thomas, Kim
AU - Chalmers, Joanne
AU - Roekevisch, Evelien
AU - Schram, Mandy
AU - Allsopp, Richard
AU - Aoki, Valeria
AU - Apfelbacher, Christian
AU - Bruijnzeel-Koomen, Carla
AU - Bruin-Weller, Marjolein
AU - Charman, Carolyn
AU - Cohen, Arnon
AU - Dohil, Magdalene
AU - Flohr, Carsten
AU - Furue, Masutaka
AU - Gieler, Uwe
AU - Hooft, Lotty
AU - Humphreys, Rosemary
AU - Ishii, Henrique Akira
AU - Katayama, Ichiro
AU - Kouwenhoven, Willem
AU - Langan, Sinéad
AU - Lewis-Jones, Sue
AU - Merhand, Stephanie
AU - Murota, Hiroyuki
AU - Murrell, Dedee F.
AU - Nankervis, Helen
AU - Ohya, Yukihiro
AU - Oranje, Arnold
AU - Otsuka, Hiromi
AU - Paul, Carle
AU - Rosenbluth, Yael
AU - Saeki, Hidehisa
AU - Schuttelaar, Marie Louise
AU - Stalder, Jean Francois
AU - Svensson, Ãke
AU - Takaoka, Roberto
AU - Wahlgren, Carl Fredrik
AU - Weidinger, Stephan
AU - Wollenberg, Andreas
AU - Williams, Hywel
PY - 2012/9/1
Y1 - 2012/9/1
N2 - The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.
AB - The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.
KW - atopic dermatitis
KW - consensus study
KW - measurement
KW - outcome domain
KW - study endpoint
UR - http://www.scopus.com/inward/record.url?scp=84864977670&partnerID=8YFLogxK
U2 - 10.1111/j.1398-9995.2012.02874.x
DO - 10.1111/j.1398-9995.2012.02874.x
M3 - Article
C2 - 22844983
AN - SCOPUS:84864977670
SN - 0105-4538
VL - 67
SP - 1111
EP - 1117
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 9
ER -